Immunocore (IMCR) Stock Forecast, Price Target & Predictions
IMCR Stock Forecast
Immunocore stock forecast is as follows: an average price target of $75.50 (represents a 125.04% upside from IMCR’s last price of $33.55) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
IMCR Price Target
The average price target for Immunocore (IMCR) is $75.50 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $100.00 to $66.00. This represents a potential 125.04% upside from IMCR's last price of $33.55.
IMCR Analyst Ratings
According to 7 Wall Street analysts, Immunocore's rating consensus is 'Buy'. The analyst rating breakdown for IMCR stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 1 'Hold' (14.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Immunocore Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 12, 2024 | Graig Suvannavejh | Mizuho Securities | $72.00 | $33.44 | 115.31% | 114.61% |
| Aug 28, 2024 | Patrick Trucchio | H.C. Wainwright | $100.00 | $35.71 | 180.03% | 198.06% |
| Aug 09, 2024 | Peter Lawson | Barclays | $66.00 | $37.92 | 74.05% | 96.72% |
| May 13, 2024 | Graig Suvannavejh | Mizuho Securities | $88.00 | $57.25 | 53.71% | 162.30% |
| May 09, 2024 | Bill Maughan | Canaccord Genuity | $67.00 | $61.32 | 9.26% | 99.70% |
| Dec 15, 2022 | Rajan Sharma | Goldman Sachs | $80.00 | $59.42 | 34.63% | 138.45% |
| Sep 09, 2022 | Michael Yee | Jefferies | $68.00 | $44.03 | 54.43% | 102.68% |
The latest Immunocore stock forecast, released on Sep 12, 2024 by Graig Suvannavejh from Mizuho Securities, set a price target of $72.00, which represents a 115.31% increase from the stock price at the time of the forecast ($33.44), and a 114.61% increase from IMCR last price ($33.55).
Immunocore Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 3 | 5 |
| Avg Price Target | $86.00 | $79.33 | $78.60 |
| Last Closing Price | $33.55 | $33.55 | $33.55 |
| Upside/Downside | 156.33% | 136.45% | 134.28% |
In the current month, the average price target of Immunocore stock is $86.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 156.33% increase as opposed to Immunocore's last price of $33.55. This month's average price target is up 8.41% compared to last quarter, and up 9.41% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 28, 2024 | Oppenheimer | Buy | Buy | Hold |
| Aug 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 09, 2024 | Needham | Buy | Buy | Hold |
| Aug 09, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Aug 09, 2024 | Barclays | Overweight | Overweight | Hold |
| Jul 10, 2024 | Needham | Buy | Buy | Hold |
| Jul 10, 2024 | Leerink Partners | Underperform | Underperform | Hold |
| Jun 03, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 24, 2024 | Oppenheimer | Buy | Buy | Hold |
| May 24, 2024 | Needham | Underperform | Underperform | Hold |
Immunocore's last stock rating was published by Oppenheimer on Aug 28, 2024. The company gave IMCR a "Buy" rating, the same as its previous rate.
Immunocore Financial Forecast
Immunocore Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $105.64M | $51.49M | - | $44.54M | $48.06M | $41.20M | $32.00M | $22.47M | $6.59M | $5.92M | $5.73M | $8.27M | $7.42M |
| Avg Forecast | $190.00M | $173.23M | $157.93M | $143.99M | $89.55M | $87.56M | $87.18M | $84.59M | $82.34M | $78.50M | $74.58M | $69.47M | $66.58M | $62.79M | $57.76M | $49.51M | $52.20M | $37.39M | $20.97M | $8.34M | $7.79M | $7.36M | $7.83M | $11.47M | $6.46M |
| High Forecast | $197.42M | $179.99M | $164.10M | $149.61M | $93.04M | $90.97M | $90.58M | $87.89M | $85.55M | $81.58M | $77.49M | $72.18M | $76.67M | $65.24M | $60.02M | $51.45M | $54.24M | $38.85M | $22.49M | $8.95M | $8.35M | $7.89M | $8.40M | $12.30M | $6.92M |
| Low Forecast | $182.73M | $166.60M | $151.89M | $138.48M | $86.12M | $84.21M | $83.84M | $81.35M | $79.19M | $73.22M | $71.73M | $66.81M | $58.22M | $60.39M | $55.55M | $47.62M | $50.21M | $35.96M | $19.81M | $7.88M | $7.35M | $6.95M | $7.40M | $10.83M | $6.10M |
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.59% | 0.82% | - | 0.90% | 0.92% | 1.10% | 1.53% | 2.69% | 0.85% | 0.81% | 0.73% | 0.72% | 1.15% |
Immunocore's average Quarter revenue forecast for Mar 24 based on 10 analysts is $69.47M, with a low forecast of $66.81M, and a high forecast of $72.18M. IMCR's average Quarter revenue forecast represents a -34.24% decrease compared to the company's last Quarter revenue of $105.64M (Dec 23).
Immunocore EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-37.54M | $14.06M | - | $-13.56M | $-19.90M | $-6.94M | $-12.02M | $-14.77M | $-36.11M | $-29.23M | $-32.71M | $-30.05M | $-17.60M |
| Avg Forecast | $-129.50M | $-118.07M | $-107.64M | $-98.14M | $-61.03M | $-59.68M | $-59.42M | $-57.65M | $-56.12M | $-53.50M | $-50.83M | $-47.35M | $-45.38M | $-42.80M | $-39.37M | $-33.75M | $-35.58M | $-33.02M | $-14.29M | $-15.89M | $-5.31M | $-5.02M | $-5.34M | $-19.39M | $-4.40M |
| High Forecast | $-124.54M | $-113.55M | $-103.52M | $-94.39M | $-58.70M | $-57.39M | $-57.15M | $-55.45M | $-53.97M | $-49.90M | $-48.89M | $-45.53M | $-39.68M | $-41.16M | $-37.86M | $-32.46M | $-34.22M | $-26.42M | $-13.50M | $-12.71M | $-5.01M | $-4.74M | $-5.04M | $-15.51M | $-4.16M |
| Low Forecast | $-134.55M | $-122.67M | $-111.84M | $-101.97M | $-63.41M | $-62.00M | $-61.74M | $-59.90M | $-58.31M | $-55.60M | $-52.82M | $-49.19M | $-52.26M | $-44.47M | $-40.90M | $-35.06M | $-36.97M | $-39.63M | $-15.33M | $-19.06M | $-5.69M | $-5.38M | $-5.73M | $-23.26M | $-4.72M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.83% | -0.33% | - | 0.40% | 0.56% | 0.21% | 0.84% | 0.93% | 6.80% | 5.83% | 6.13% | 1.55% | 4.00% |
11 analysts predict IMCR's average Quarter EBITDA for Dec 23 to be $-45.38M, with a high of $-39.68M and a low of $-52.26M. This is -422.82% lower than Immunocore's previous annual EBITDA (Sep 23) of $14.06M.
Immunocore Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-26.42M | $1.90M | - | $-16.70M | $-25.20M | $6.23M | $-6.12M | $-16.13M | $-39.39M | $-30.13M | $-32.96M | $-29.04M | $-18.88M |
| Avg Forecast | $-28.50M | $-27.47M | $-25.38M | $-24.35M | $-21.08M | $-18.15M | $-16.18M | $-17.13M | $-17.62M | $-14.50M | $-18.81M | $-14.66M | $-9.81M | $-14.45M | $-15.38M | $-14.07M | $1.08M | $-34.05M | $-30.17M | $-17.35M | $-39.90M | $-41.60M | $-34.97M | $-18.73M | $-39.00M |
| High Forecast | $-27.08M | $-26.10M | $-24.12M | $-23.14M | $-20.03M | $-17.24M | $-15.38M | $-16.27M | $-16.74M | $-6.07M | $-17.87M | $-13.93M | $-2.45M | $-13.73M | $-14.61M | $-13.37M | $1.14M | $-27.24M | $-28.00M | $-13.88M | $-37.03M | $-38.60M | $-32.45M | $-14.99M | $-36.19M |
| Low Forecast | $-29.94M | $-28.86M | $-26.67M | $-25.58M | $-22.15M | $-19.07M | $-17.00M | $-18.00M | $-18.51M | $-25.63M | $-19.76M | $-15.41M | $-16.81M | $-15.19M | $-16.16M | $-14.78M | $1.03M | $-40.86M | $-33.01M | $-20.82M | $-43.66M | $-45.51M | $-38.26M | $-22.48M | $-42.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.69% | -0.13% | - | 1.19% | -23.32% | -0.18% | 0.20% | 0.93% | 0.99% | 0.72% | 0.94% | 1.55% | 0.48% |
Immunocore's average Quarter net income forecast for Dec 23 is $-9.81M, with a range of $-16.81M to $-2.45M. IMCR's average Quarter net income forecast represents a -615.06% decrease compared to the company's last Quarter net income of $1.90M (Sep 23).
Immunocore SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $64.19M | $10.99M | - | $33.30M | $43.14M | $25.88M | $24.51M | $20.11M | $24.37M | $20.05M | $23.80M | $20.18M | $14.17M |
| Avg Forecast | $296.58M | $270.40M | $246.53M | $224.77M | $139.78M | $136.67M | $136.09M | $132.04M | $128.53M | $122.54M | $116.42M | $108.43M | $103.94M | $98.02M | $90.16M | $77.29M | $81.49M | $22.65M | $32.73M | $13.02M | $12.15M | $11.49M | $12.23M | $17.90M | $10.08M |
| High Forecast | $308.16M | $280.95M | $256.15M | $233.54M | $145.23M | $142.01M | $141.40M | $137.19M | $133.54M | $127.34M | $120.96M | $112.66M | $119.68M | $101.84M | $93.68M | $80.30M | $84.67M | $27.18M | $35.10M | $13.96M | $13.03M | $12.32M | $13.11M | $19.20M | $10.81M |
| Low Forecast | $285.23M | $260.05M | $237.10M | $216.17M | $134.43M | $131.44M | $130.88M | $126.99M | $123.61M | $114.29M | $111.96M | $104.28M | $90.89M | $94.27M | $86.71M | $74.33M | $78.37M | $18.12M | $30.92M | $12.30M | $11.48M | $10.85M | $11.55M | $16.91M | $9.52M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.62% | 0.11% | - | 0.43% | 0.53% | 1.14% | 0.75% | 1.54% | 2.00% | 1.75% | 1.95% | 1.13% | 1.41% |
Immunocore's average Quarter SG&A projection for Mar 24 is $108.43M, based on 10 Wall Street analysts, with a range of $104.28M to $112.66M. The forecast indicates a 68.91% rise compared to IMCR last annual SG&A of $64.19M (Dec 23).
Immunocore EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $0.04 | - | $-0.35 | $-0.54 | $0.13 | $-0.14 | $-0.37 | $-0.90 | $-0.69 | $-0.75 | $-0.76 | $-0.49 |
| Avg Forecast | $-0.57 | $-0.55 | $-0.51 | $-0.49 | $-0.42 | $-0.36 | $-0.32 | $-0.34 | $-0.35 | $-0.29 | $-0.38 | $-0.29 | $-0.20 | $-0.29 | $-0.31 | $-0.28 | $0.02 | $-0.25 | $-0.60 | $-0.84 | $-0.80 | $-0.83 | $-0.70 | $-0.60 | $-0.78 |
| High Forecast | $-0.54 | $-0.52 | $-0.48 | $-0.46 | $-0.40 | $-0.34 | $-0.31 | $-0.33 | $-0.33 | $-0.12 | $-0.36 | $-0.28 | $-0.05 | $-0.27 | $-0.29 | $-0.27 | $0.02 | $-0.24 | $-0.56 | $-0.78 | $-0.74 | $-0.77 | $-0.65 | $-0.56 | $-0.72 |
| Low Forecast | $-0.60 | $-0.58 | $-0.53 | $-0.51 | $-0.44 | $-0.38 | $-0.34 | $-0.36 | $-0.37 | $-0.51 | $-0.40 | $-0.31 | $-0.34 | $-0.30 | $-0.32 | $-0.30 | $0.02 | $-0.26 | $-0.66 | $-0.91 | $-0.87 | $-0.91 | $-0.77 | $-0.66 | $-0.85 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | -0.14% | - | 1.24% | -24.99% | -0.52% | 0.23% | 0.44% | 1.13% | 0.83% | 1.07% | 1.27% | 0.63% |
According to 11 Wall Street analysts, Immunocore's projected average Quarter EPS for Dec 23 is $-0.20, with a low estimate of $-0.34 and a high estimate of $-0.05. This represents a -590.20% decrease compared to IMCR previous annual EPS of $0.04 (Sep 23).
Immunocore Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.29 | $33.86 | 1378.60% | Buy |
| ERAS | Erasca | $2.97 | $7.00 | 135.69% | Buy |
| KALV | KalVista Pharmaceuticals | $11.14 | $26.00 | 133.39% | Buy |
| IMCR | Immunocore | $33.55 | $75.50 | 125.04% | Buy |
| LRMR | Larimar Therapeutics | $7.20 | $14.50 | 101.39% | Buy |
| LYRA | Lyra Therapeutics | $0.28 | $0.50 | 78.57% | Hold |
| DSGN | Design Therapeutics | $5.54 | $9.67 | 74.55% | Buy |
| VRDN | Viridian Therapeutics | $22.06 | $37.83 | 71.49% | Buy |
| MIRM | Mirum Pharmaceuticals | $41.12 | $54.50 | 32.54% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| NUVL | Nuvalent | $87.45 | $107.33 | 22.73% | Buy |
| PCVX | Vaxcyte | $116.00 | $124.14 | 7.02% | Buy |
| ACLX | Arcellx | $76.89 | $61.00 | -20.67% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
IMCR Forecast FAQ
Is Immunocore a good buy?
Yes, according to 7 Wall Street analysts, Immunocore (IMCR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 85.71% of IMCR's total ratings.
What is IMCR's price target?
Immunocore (IMCR) average price target is $75.5 with a range of $66 to $100, implying a 125.04% from its last price of $33.55. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Immunocore stock go up soon?
According to Wall Street analysts' prediction for IMCR stock, the company can go up by 125.04% (from the last price of $33.55 to the average price target of $75.5), up by 198.06% based on the highest stock price target, and up by 96.72% based on the lowest stock price target.
Can Immunocore stock reach $50?
IMCR's average twelve months analyst stock price target of $75.5 supports the claim that Immunocore can reach $50 in the near future.
What is Immunocore's current price target trend?
2 Wall Street analysts forecast a $86 price target for Immunocore (IMCR) this month, up 156.33% from its last price of $33.55. Compared to the last 3 and 12 months, the average price target increased by 136.45% and increased by 134.28%, respectively.
What are Immunocore's analysts' financial forecasts?
Immunocore's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $348.87M (high $362.48M, low $335.52M), average EBITDA is $-238M (high $-229M, low $-247M), average net income is $-72.531M (high $-68.922M, low $-76.21M), average SG&A $544.57M (high $565.82M, low $523.73M), and average EPS is $-1.45 (high $-1.378, low $-1.524). IMCR's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $665.15M (high $691.11M, low $639.7M), average EBITDA is $-453M (high $-436M, low $-471M), average net income is $-106M (high $-100M, low $-111M), average SG&A $1.04B (high $1.08B, low $998.55M), and average EPS is $-2.113 (high $-2.008, low $-2.221).
Did the IMCR's actual financial results beat the analysts' financial forecasts?
Based on Immunocore's last annual report (Dec 2023), the company's revenue was $249.43M, beating the average analysts forecast of $236.65M by 5.40%. Apple's EBITDA was $-59.649M, missing the average prediction of $-161M by -63.02%. The company's net income was $-55.287M, beating the average estimation of $-53.709M by 2.94%. Apple's SG&A was $144.5M, missing the average forecast of $369.4M by -60.88%. Lastly, the company's EPS was $-0.0011, missing the average prediction of $-1.074 by -99.90%. In terms of the last quarterly report (Dec 2023), Immunocore's revenue was $105.64M, beating the average analysts' forecast of $66.58M by 58.65%. The company's EBITDA was $-37.543M, missing the average prediction of $-45.382M by -17.27%. Immunocore's net income was $-26.417M, beating the average estimation of $-9.807M by 169.38%. The company's SG&A was $64.2M, missing the average forecast of $103.94M by -38.24%. Lastly, the company's EPS was $-0.0005, missing the average prediction of $-0.196 by -99.75%